{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:34:14Z","timestamp":1792985654049,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herein we report for baricitinib drug retention, predictors thereof and clinical responses in rheumatoid arthritis (RA) patients with a special focus in comorbidities. Prospective, multicenter, observational study of RA patients starting baricitinib because of active disease. Patients were followed every 3\u00a0months for 12\u00a0months. The primary endpoint was baricitinib retention at 12\u00a0months; predictors for survival and clinical responses at 6\u00a0months were secondary endpoints. Retention rate was estimated by Kaplan\u2013Meier (K-M) while predictors of discontinuation by Cox regression. We recruited 135 patients, 93.3% females, mean (standard deviation-SD) age 56.1 (10.1) years, median (interquartile range) disease duration 57 (90) months. 18.5% started baricitinib as first line targeted therapy. 35.9% (28\/88) and 44.1% (26\/59) achieved DAS28 remission\/low disease activity (LDA) at 6 and 12\u00a0months respectively. Baricitinib retention at 12\u00a0months was 68.9%. K-M analysis showed that hypertension (p=0.049), latent tuberculosis infection (LTBi) (p=0.007) and depression (p=0.005) were associated to lower retention, while multivariate analysis showed that depression [Hazard ratio (HR) 2.715, p=0.007] and LTBi (HR 2.519, p=0.020) predicted baricitinib discontinuation. Analysis for patients on therapy for at least 6\u00a0months showed that together with hypertension (HR 2.477, p=0.022) and LTBi (HR 3.761, p=0.023), higher DAS28 at 6\u00a0months (HR 1.434, p=0.024) predicted baricitinib discontinuation at 12\u00a0months. In established RA, 68.9% of the patients remained on baricitinib at 12\u00a0months and had an improvement of disease activity. Mostly comorbidities contributed to baricitinib persistence, supporting their importance as factors to be addressed to optimize RA clinical care.<\/jats:p>","DOI":"10.1007\/s00296-026-06313-y","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:20:56Z","timestamp":1791188456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-1304","authenticated-orcid":false,"given":"Irini","family":"Flouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-2488","authenticated-orcid":false,"given":"Antonios","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5708-7182","authenticated-orcid":false,"given":"Konstantina","family":"Zoupidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-6918","authenticated-orcid":false,"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-0235","authenticated-orcid":false,"given":"Dimitrios","family":"Nezis-Katsifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9009-0784","authenticated-orcid":false,"given":"Elena","family":"Sambatakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-4016","authenticated-orcid":false,"given":"Nestor","family":"Avgoustidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-2449","authenticated-orcid":false,"given":"Argyro","family":"Repa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-0326","authenticated-orcid":false,"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"6","key":"6313_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","volume":"85","author":"JS Smolen","year":"2025","unstructured":"Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R et al (2025) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis 85(6):991\u20131009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6313_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"3","key":"6313_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthr Rheumatol 69(3):506\u2013517","journal-title":"Arthr Rheumatol"},{"issue":"13","key":"6313_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"4","key":"6313_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"9","key":"6313_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D et al (2025) Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries. Arthr Rheumatol 77(9):1194\u20131204","journal-title":"Arthr Rheumatol"},{"issue":"6","key":"6313_CR7","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Smolen JS, Takeuchi T, Burmester G, Brinker D, Rooney TP et al (2020) Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol 2(6):e347\u2013e357","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"6313_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6313_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V et al (2021) Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthr Rheumatol 73(5):779\u2013788","journal-title":"Arthr Rheumatol"},{"issue":"2","key":"6313_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3899\/jrheum.210346","volume":"49","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Kartman CE, Xie L, Beattie S, Schlichting D, Mo D et al (2022) Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: results from RA-BEYOND. J Rheumatol 49(2):133\u2013141","journal-title":"J Rheumatol"},{"issue":"5","key":"6313_CR11","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","volume":"60","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Xie L, Jia B, Taylor PC, Burmester G, Tanaka Y et al (2021) Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology (Oxford) 60(5):2256\u20132266","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"6313_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","volume":"63","author":"R Caporali","year":"2024","unstructured":"Caporali R, Taylor PC, Aletaha D, Sanmarti R, Takeuchi T, Mo D et al (2024) Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Rheumatology (Oxford) 63(10):2799\u20132809","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"6313_CR13","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1093\/rheumatology\/kead074","volume":"62","author":"CJ Edwards","year":"2023","unstructured":"Edwards CJ, Mount J, Meeks A, Gulati T, Zaremba-Pechmann L, Sheesh M et al (2023) Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA registry data. Rheumatology (Oxford) 62(10):3400\u20133408","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"6313_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","volume":"9","author":"B Hernandez-Cruz","year":"2022","unstructured":"Hernandez-Cruz B, Rosas J, Diaz-Torne C, Belzunegui J, Garcia-Vicuna R, Inciarte-Mundo J et al (2022) Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (the ORBIT-RA study). Rheumatol Ther 9(2):589\u2013608","journal-title":"Rheumatol Ther"},{"issue":"6","key":"6313_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","volume":"10","author":"R Alten","year":"2023","unstructured":"Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Ostor A, Ng KJ et al (2023) Comparative effectiveness, time to discontinuation, and patient-reported outcomes with baricitinib in rheumatoid arthritis: 2-year data from the multinational, prospective observational RA-BE-REAL study in European patients. Rheumatol Ther 10(6):1575\u20131595","journal-title":"Rheumatol Ther"},{"issue":"1","key":"6313_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-022-02826-6","volume":"24","author":"A Bertsias","year":"2022","unstructured":"Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E et al (2022) Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Arthritis Res Ther 24(1):132","journal-title":"Arthritis Res Ther"},{"key":"6313_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006333","author":"A Temiz","year":"2025","unstructured":"Temiz A, Tascilar K, Kleyer A, Hueber AJ, Hartmann F, Schett G et al (2025) Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2025-006333","journal-title":"RMD Open"},{"issue":"2","key":"6313_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA registry. Rheumatol Ther 4(2):489\u2013502","journal-title":"Rheumatol Ther"},{"key":"6313_CR19","doi-asserted-by":"publisher","first-page":"1759720X2413080","DOI":"10.1177\/1759720X241308027","volume":"16","author":"DJ Park","year":"2024","unstructured":"Park DJ, Jeong H, Choi SE, Kang JH, Lee SS (2024) Impact of obesity on clinical outcomes and treatment continuation in rheumatoid arthritis patients receiving non-TNF-targeted therapies. Ther Adv Musculoskelet Dis 16:1759720X241308027","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"6313_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","volume":"82","author":"F Iannone","year":"2015","unstructured":"Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G (2015) Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients. Joint Bone Spine 82(3):187\u2013191","journal-title":"Joint Bone Spine"},{"issue":"1","key":"6313_CR21","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1038\/s41598-021-90442-w","volume":"11","author":"A Prior-Espanol","year":"2021","unstructured":"Prior-Espanol A, Sanchez-Piedra C, Campos J, Manero FJ, Perez-Garcia C, Bohorquez C et al (2021) Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry. Sci Rep 11(1):11091","journal-title":"Sci Rep"},{"issue":"7","key":"6313_CR22","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1007\/s10067-026-08175-y","volume":"45","author":"S Abdellaoui","year":"2026","unstructured":"Abdellaoui S, Al Tabaa O, Hilliquin S, d\u2019Alessandro R, Hecquet S, Thomas M et al (2026) Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study. Clin Rheumatol 45(7):4071\u20134081","journal-title":"Clin Rheumatol"},{"issue":"4","key":"6313_CR23","doi-asserted-by":"publisher","first-page":"e0250877","DOI":"10.1371\/journal.pone.0250877","volume":"16","author":"CT Lin","year":"2021","unstructured":"Lin CT, Huang WN, Tsai WC, Chen JP, Hung WT, Hsieh TY et al (2021) Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: analysis from the TRA Clinical Electronic Registry. PLoS ONE 16(4):e0250877","journal-title":"PLoS ONE"},{"issue":"10","key":"6313_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/acr2.11175","volume":"2","author":"LW Desilet","year":"2020","unstructured":"Desilet LW, England BR, Michaud K, Barton JL, Mikuls TR, Baker JF (2020) Posttraumatic stress disorder, depression, anxiety, and persistence of methotrexate and TNF inhibitors in patients with rheumatoid arthritis. ACR Open Rheumatol 2(10):555\u2013564","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"6313_CR25","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/S2665-9913(26)00041-X","volume":"8","author":"W Xie","year":"2026","unstructured":"Xie W, Chen T, Chen Y, Zhang Z, Xiao S (2026) Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis. Lancet Rheumatol 8(6):e425\u2013e437","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"6313_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00296-020-04667-5","volume":"41","author":"DA Pappas","year":"2021","unstructured":"Pappas DA, Litman HJ, Lesperance T, Kricorian G, Karis E, Rebello S et al (2021) Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of CORRONA registry data. Rheumatol Int 41(2):381\u2013390","journal-title":"Rheumatol Int"},{"key":"6313_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003808","author":"A Bertsias","year":"2024","unstructured":"Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S et al (2024) Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with \u2018difficult to treat\u2019 rheumatoid arthritis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003808","journal-title":"RMD Open"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06313-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:01:31Z","timestamp":1792983691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06313-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6313"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06313-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"5 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prodromos Sidiropoulos: grants, consulting fees or honoraria by Abbvie, Pfizer, Lilly, Amgen, MSD, Roche, Novartis, UCB, Janssen, through the \u201cUniversity of Crete Special Account for Research\u201d. George Bertsias: grants, consulting fees or honoraria by J & J Lilly, Astra-Zeneca, Boehringer Ingelheim Amgen, Roche, Novartis, UCB, Janssen, through the \u201cUniversity of Crete Special Account for Research\u201d. Christos Koutsianas: speaker\u2019s fees and honoraria for advisory boards from the following companies: Genesis Pharma, Abbvie, Novartis, Pharmaserve-Lilly, Pfizer, Aenorasis, UCB, GSK, Boehringer, Sobi, J & J, Sandoz, Amgen, Vianex. None is related to this particular study. Dimitrios Vassilopoulos: grants\/research support\/speaker\/honoraria\/consultation fees: Abbvie, Astra-Zeneca, Boehringer Ingelheim, Genesis-Pharma, Lilly, GSK, Pfizer, UCB (through Special Account for Research Grants-S.A.R.G., National and Kapodistrian University of Athens, Athens, Greece). Maria Tektonidou: consultant fees and grants from AbbVie, GSK, BMS, Novartis, Otsuka and UCB, all through the Special Account for Research Funding of the National and Kapodistrian University of Athens, Medical School. Petros Sfikakis: grants and personal fees from Abbvie, Boehringer Ingelheim, Eli-Lilly, MSD, Pfizer and UCB. George Fragoulis: grants and consultancies\/speaker fees from Abbvie, Boehringer Ingelheim, Eli-Lilly, MSD, Pfizer, UCB, Novartis, Amgen, Johnson and Johnson. Irini Flouri, Antonios Bertsias, Konstantina Zoupidou, Dimitrios Nezis-Katsifis, Elena Sambatakaki, Nestor Avgoustidis, Argyro Repa: no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"University Hospital of Heraklion ethics committee approval: 1341 16\/2\/2022. \u201cLaiko\" Hospital ethics committee approval: 125\/2024. \u201cAttikon\u201d Hospital ethics committee approval: 1563\/17\u201310-19. General Hospital of Athens \"Hippocration\" ethics committee approval: 16-11th\/12\u201304-2022.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"276"}}